ArticleMolecular genetics and metabolism2026
Diagnostic and therapeutic applications of the glycan biomarker H3N2b in GM1 Gangliosidosis.
Article in Molecular genetics and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
GM1 gangliosidosis is a progressive lysosomal storage disorder caused by β-galactosidase deficiency, resulting in accumulation of GM1 ganglioside and related glycoconjugates. Current diagnostic approaches rely on enzymatic and genetic testing but do not provide dynamic measures of substrate accumulation or therapeutic response. The oligosaccharide H3N2b has previously been identified as a potential biomarker of impaired β-galactosidase activity. In this study, H3N2b was quantified in plasma, urine, and cerebrospinal fluid (CSF) from patients with GM1 gangliosidosis (n = 47 plasma/urine; n = 34 CSF) and age- and sex-matched controls using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay. A limited set of comparator lysosomal storage disorder samples was also analyzed to provide preliminary assessment of biomarker specificity. Longitudinal H3N2b measurements were obtained from participants receiving intravenous adeno-associated virus serotype 9 (AAV9)-mediated GLB1 gene therapy. H3N2b concentrations were significantly elevated in GM1 gangliosidosis compared with controls in plasma (cutoff 6.2 ng/mL; 100% sensitivity and specificity), urine (0.65 ng/μg creatinine; 99.3% sensitivity, 100% specificity), and CSF (5.1 ng/mL; 98.9% sensitivity, 100% specificity). H3N2b levels correlated with disease severity and were not influenced by age or sex. Among the comparator disorders analyzed, H3N2b values were generally below GM1 diagnostic cutoffs, although the comparator analysis was limited by sample availability and did not include several relevant disorders and CSF. In gene therapy recipients, plasma, urine, and CSF H3N2b concentrations decreased following treatment and closely paralleled changes in β-galactosidase activity, indicating pharmacodynamic responsiveness. These findings provide a cross-matrix clinical evaluation of H3N2b as a diagnostic and therapeutic biomarker for GM1 gangliosidosis and support its utility as a candidate biochemical biomarker to aid diagnosis and monitor treatment-associated biochemical changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.